| Symbol | GNPX |
|---|---|
| Name | GENPREX, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3300 BEE CAVE ROAD,SUITE 650-227, AUSTIN, Texas, 78746, United States |
| Telephone | +1 877 774-4679 |
| Fax | — |
| — | |
| Website | https://www.genprex.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001595248 |
| Description | Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprexs technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprexs oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Genprex, Inc. <b>Filed:</b> 2026-05-11 <b>AccNo:</b> 0001493152-26-022311 <b>Size:</b> 11 KB
Read moreGenprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Read moreNew Form ARS - Genprex, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001437749-26-013907 <b>Size:</b> 5 MB
Read more(70% Positive) GENPREX, INC. (GNPX) Announces Clinical Development Update
Read moreGenprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell
Read morePositive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
Read morePositive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
Read moreGenprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
Read moreGenprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual M
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05703971 | Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-S… | Phase1 | Small Cell Lung Cancer Extensive Stage | Recruiting | 2024-05-09 | 2027-08-01 | ClinicalTrials.gov |
| NCT05062980 | Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previou… | Phase1 | Non Small Cell Lung Cancer | Terminated | 2022-03-30 | 2025-02-03 | ClinicalTrials.gov |
| NCT04486833 | Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lu… | Phase1 | Carcinoma, Non-Small Cell Lung | Recruiting | 2021-09-03 | 2029-03-01 | ClinicalTrials.gov |
| NCT01455389 | TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer | Phase1 | Lung Cancer | Terminated | 2014-02-01 | 2020-09-28 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Diphenhydramine | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT01455389 |
| Dexamethasone | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT01455389 |
| Erlotinib | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT01455389 |
| DOTAP:Chol-TUSC2 | Other | Phase PHASE1 | Lung Cancer | TERMINATED | NCT01455389 |
| Investigator's Treatment of Choice | Drug | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT05062980 |
| ramucirumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT05062980 |
| docetaxel | Other | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT05062980 |
| pembrolizumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT05062980 |
| quaratusugene ozeplasmid | Other | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT05062980 |
| atezolizumab | Other | Phase PHASE1 | Small Cell Lung Cancer Extensive Stage | RECRUITING | NCT05703971 |
| quaratusugene ozeplasmid | Other | Phase PHASE1 | Small Cell Lung Cancer Extensive Stage | RECRUITING | NCT05703971 |
| Platinum-Based Chemotherapy | Drug | Phase PHASE1 | Carcinoma, Non-Small Cell Lung | RECRUITING | NCT04486833 |
| osimertinib | Other | Phase PHASE1 | Carcinoma, Non-Small Cell Lung | RECRUITING | NCT04486833 |
| quaratusugene ozeplasmid | Other | Phase PHASE1 | Carcinoma, Non-Small Cell Lung | RECRUITING | NCT04486833 |
| atezolizumab | BIOLOGICAL | Phase PHASE1 | Small Cell Lung Cancer Extensive Stage | RECRUITING | NCT05703971 |
| Investigator's Treatment of Choice | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT05062980 |
| ramucirumab | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT05062980 |
| docetaxel | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT05062980 |
| pembrolizumab | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | TERMINATED | NCT05062980 |
| Platinum-Based Chemotherapy | DRUG | Phase PHASE1 | Carcinoma, Non-Small Cell Lung | RECRUITING | NCT04486833 |
| osimertinib | DRUG | Phase PHASE1 | Carcinoma, Non-Small Cell Lung | RECRUITING | NCT04486833 |
| quaratusugene ozeplasmid | BIOLOGICAL | Phase PHASE1 | Small Cell Lung Cancer Extensive Stage | RECRUITING | NCT05703971 |
| Diphenhydramine | DRUG | Phase PHASE1 | Lung Cancer | TERMINATED | NCT01455389 |
| Dexamethasone | DRUG | Phase PHASE1 | Lung Cancer | TERMINATED | NCT01455389 |
| Erlotinib | DRUG | Phase PHASE1 | Lung Cancer | TERMINATED | NCT01455389 |
| DOTAP:Chol-TUSC2 | DRUG | Phase PHASE1 | Lung Cancer | TERMINATED | NCT01455389 |